Lithuania vs Mus: Previously treated cases tested for RR-/MDR-TB (%)
Lithuania
100.0%
in 2024
Mus
100.0%
in 2022
Lithuania rank
1st
Mus rank
1st
Previously treated cases tested for RR-/MDR-TB (%) over time
- Lithuania
- Mus
How they compare
Lithuania currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 3 times across 18 shared years of data; in 2005 it was Lithuania ahead.
Lithuania ranks 1st and Mus ranks 1st of 180 countries.
Lithuania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 98.4% | 92.0% | 6.4% | Lithuania |
| 2010s | 100.0% | 96.0% | 4.0% | Lithuania |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Lithuania or Mus?
- Lithuania, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Lithuania and Mus?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Mus?
- 18 years are reported by both, from 2005 to 2022.
- How do Lithuania and Mus rank globally for previously treated cases tested for rr-/mdr-tb?
- Lithuania ranks 1st and Mus ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.